Denali 10-Q: $70.1M Q3 Profit Is a PRV Gain; $1.0B Cash, $345.6M Nine-Month Burn
DNLI sits 41% above its 52-week low of $13.75.
Summary
Denali's Q3 profit of $70.1 million is entirely a one-time $194.0 million PRV sale gain; operations still lost $126.8 million. The 10-Q adds $1.0 billion of cash, a $209.7 million royalty liability and $345.6 million of nine-month operating burn.
Key Events · Earnings and Guidance · DNLI
-
Q3 Profit Is a One-Time PRV Gain
Net income of $70.1 million, or $0.37 per diluted share, includes a $194.0 million net gain on the July 2026 sale of the rare pediatric disease priority review voucher; the operating loss was $126.8 million for the quarter.
-
AVLAYAH Revenue $17.8M, Q4 Guided Higher
Second full commercial quarter produced $17.8 million of net product revenue ($21.4 million for nine months); Q4 2026 net product revenue is guided to $30.0-32.0 million with payer coverage above 70% of U.S. commercial lives.
-
Cash $1.0B Against $345.6M Burn
Cash, cash equivalents and marketable securities totaled $1.0 billion at September 30, 2026; nine-month operating cash use was $345.6 million versus $314.1 million a year earlier, and management says funding lasts at least twelve months.
-
Royalty Pharma Liability Now $209.7M
The $200.0 million March 2026 synthetic royalty proceeds are carried as a $209.7 million liability at a roughly 12% effective annual interest rate, generating $12.1 million of non-cash interest expense over nine months; a further $75.0 million is contingent on EMA approval by December 31, 2029.
Analysis · DNLI · Life Sciences
The headline profit is accounting, not operations: $70.1 million of Q3 net income rests on a one-time $194.0 million net gain from selling the priority review voucher, while the core business still lost $126.8 million from operations in the quarter. Beyond this morning's release, the full 10-Q adds the balance sheet and cash detail — $1.0 billion of cash and securities against a new $209.7 million Royalty Pharma liability, and $345.6 million of operating cash burn over nine months, up from $314.1 million a year earlier. AVLAYAH's second full quarter brought $17.8 million of net product revenue, and management guides Q4 to $30.0-32.0 million, so the commercial ramp is the number that matters from here. Also newly disclosed: CEO Ryan Watts adopted a 10b5-1 plan in August covering up to 376,751 shares, and director David Schenkein adopted one for 51,083 shares.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DNLI was trading at $19.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $13.75 to $27.30. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.